These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25551981)

  • 1. [FGF23 in CKD-MBD].
    Fukumoto S
    Nihon Jinzo Gakkai Shi; 2014; 56(8):1210-7. PubMed ID: 25551981
    [No Abstract]   [Full Text] [Related]  

  • 2. [CKD-MBD as a predictor of mortality].
    Hamano T
    Nihon Jinzo Gakkai Shi; 2014; 56(8):1233-42. PubMed ID: 25551984
    [No Abstract]   [Full Text] [Related]  

  • 3. Klotho/FGF23 Axis in CKD.
    Tsuchiya K; Nagano N; Nitta K
    Contrib Nephrol; 2015; 185():56-65. PubMed ID: 26023015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New Developments in CKD-MBD. Why is phosphate overload harmful?].
    Kuroo M
    Clin Calcium; 2014 Dec; 24(12):1785-92. PubMed ID: 25423923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?].
    Komaba H
    Clin Calcium; 2014 Dec; 24(12):1771-8. PubMed ID: 25423921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-renal-Related Mechanisms of FGF23 Pathophysiology.
    Hanudel MR; Laster M; Salusky IB
    Curr Osteoporos Rep; 2018 Dec; 16(6):724-729. PubMed ID: 30353318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Women and CKD-mineral and bone disorder.
    Ho LT; Sprague SM
    Adv Chronic Kidney Dis; 2013 Sep; 20(5):423-6. PubMed ID: 23978548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New Developments in CKD-MBD. Strategies for the management of predilalysis CKD-MBD].
    Ando R
    Clin Calcium; 2014 Dec; 24(12):1845-51. PubMed ID: 25423931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone disease in the field of CKD-MBD].
    Yajima A; Tsuchiya K; Yokota H; Nitta K
    Clin Calcium; 2016 Jun; 26(6):875-80. PubMed ID: 27230843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.
    Fang Y; Ginsberg C; Seifert M; Agapova O; Sugatani T; Register TC; Freedman BI; Monier-Faugere MC; Malluche H; Hruska KA
    J Am Soc Nephrol; 2014 Aug; 25(8):1760-73. PubMed ID: 24578135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bone metabolism and cardiovascular function update. α-klotho/FGF23 system; a new insight into the field of mineral homeostasis and the pathogeneses of aging-associated syndromes and the complications of chronic kidney disease].
    Nabeshima YI
    Clin Calcium; 2014 Jul; 24(7):37-43. PubMed ID: 24976054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of bone in CKD-mediated mineral and vascular disease.
    Khouzam NM; Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2015 Sep; 30(9):1379-88. PubMed ID: 25168424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
    Cozzolino M; Bruschetta E; Cusi D; Montanari E; Giovenzana ME; Galassi A
    Expert Opin Pharmacother; 2012 Nov; 13(16):2337-53. PubMed ID: 23033914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CKD-MBD in all CKD stages: integration of basic and clinical research].
    Hamano T
    Nihon Jinzo Gakkai Shi; 2015; 57(8):1331-41. PubMed ID: 26817162
    [No Abstract]   [Full Text] [Related]  

  • 15. An introduction to CKD-MBD research: restart for the future.
    Fukagawa M; Inaba M; Yokoyama K; Shigematsu T; Ando R; Miyamoto KI;
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):1-3. PubMed ID: 28083765
    [No Abstract]   [Full Text] [Related]  

  • 16. [New Developments in CKD-MBD. Molecular mechanisms of intestinal and renal phosphate transport].
    Segawa H; Ikuta K; Miyamoto K
    Clin Calcium; 2014 Dec; 24(12):1793-9. PubMed ID: 25423924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a quantitative systems pharmacology model of chronic kidney disease: metabolic bone disorder.
    Gaweda AE; McBride DE; Lederer ED; Brier ME
    Am J Physiol Renal Physiol; 2021 Feb; 320(2):F203-F211. PubMed ID: 33308018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New Developments in CKD-MBD. How to "Thinking Global! Acting Local" for treating CKD-MBD].
    Tsukamoto Y
    Clin Calcium; 2014 Dec; 24(12):1757-61. PubMed ID: 25423919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The latest clinical research findings in the field of CKD-MBD].
    Hamano T
    Nihon Jinzo Gakkai Shi; 2015; 57(8):1297-302. PubMed ID: 26817155
    [No Abstract]   [Full Text] [Related]  

  • 20. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
    Manns BJ; Hodsman A; Zimmerman DL; Mendelssohn DC; Soroka SD; Chan C; Jindal K; Klarenbach S
    Am J Kidney Dis; 2010 May; 55(5):800-12. PubMed ID: 20438984
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.